Results 101 to 110 of about 184,499 (325)
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]
, 2016 Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G +2 more
core +1 more source
Deep Learning‐Powered Scalable Cancer Organ Chip for Cancer Precision Medicine
Advanced Science, EarlyView.This scalable, low‐cost Organ Chip platform, made via injection molding, uses capillary pinning for hydrogel confinement and supports versatile tissue coculture and robust imaging. Deep learning enables label‐free, sensitive phenotypic analysis.
Yu‐Chieh Yuan +24 more
wiley +1 more source
Cancer Management and Research, 2017 Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F +5 more
doaj
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Neoplasia: An International Journal for Oncology Research, 2012 Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine.
Venkatasubbaiah A. Venkatesha +8 more
doaj +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Jurnal Urologi Indonesia, 2019 Objective: To determine the differences of apoptosis effect between the combination of meloxicam and gemcitabine-carboplatin compared to gemcitabine-carboplatin alone as the standard of chemotherapy care in urothelial carcinoma culture cells.
Ananta Cahyo Nugroho +3 more
doaj +1 more source
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. [PDF]
PLoS ONE, 2013 Gemcitabine is among the most efficacious and widely used antimetabolite agents. Its molecular targets are ribonucleotide reductase M1 (RRM1) and elongating DNA.
Jun Zhou +6 more
doaj +1 more source
Autophagy and urothelial carcinoma of the bladder: A review. [PDF]
, 2016 The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan +1 more
core +2 more sources
Advanced Science, EarlyView.A targeted metabologenomic strategy integrating genomic and metabolomic hallmarks enabled the discovery of two new thioamides, thiogochangamides A and B, from bacteria. Their absolute configurations, previously unresolved within the thioviridamide family, were fully assigned through various chemical derivatizations and computational analysis ...
Young Eun Du +18 more
wiley +1 more source
Molecular Oncology, 2018 Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear.
Lei You +9 more
doaj +1 more source